以下是由国际间重症专家学者组成的FLCCC联盟所提出的，
以伊维菌素为主治疗新冠肺炎COVID-19的
预防方案、早期门诊治疗方案、和晚期住院治疗方案
出处连结:
预防方法、早期门诊治疗方法:https://reurl.cc/W31gKk
最新更新日期:2021年4月26日
晚期住院治疗方法: https://reurl.cc/1YmWOX
最新更新日期:2021年6月8日
文长，慢读
原文英文，翻译:GOOGLE翻译+GOOGLE搜寻
..............................................................................................................................
预防方法、早期门诊治疗方案:https://reurl.cc/W31gKk
I-MASK+
PREVENTION & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19
P.1
PREVENTION PROTOCOL 预防方案
lvermectin1 Prevention for high risk individuals
伊维菌素1 高危人群的预防:
0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours, then one dose weekly*
每剂 0.2 毫克/公斤（随餐或餐后服用）——今天一剂，48 小时后重复，然后每周一剂*
* The dosing may be updated as further scientific studies emerge.
随着进一步科学研究的出现，剂量可能会更新。
1 The safety of ivermectin in pregnancy has not been established. A discussion of benefits vs. risks with your provider is required prior to use, particularly in the 1st trimester.
1 伊维菌素在妊娠期的安全性尚未确定。 使用前需要与您的提供者讨论收益与风险的关系，尤其是在孕早期。
......................
Post COVID-19 exposure prevention2
COVID-19 后暴露预防2
2 To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask
2 如果家庭成员为 COVID-19 阳性，或者您长时间接触 COVID-19 阳性患者而未戴口罩时使用
0.2 mg/kg per dose (take with or after meals) ?— one dose today, repeat after 48 hours*
每剂 0.2 毫克/公斤（随餐或餐后服用）——今天一剂，48 小时后重复，然后每周一剂*
* The dosing may be updated as further scientific studies emerge.
随着进一步科学研究的出现，剂量可能会更新。
Vitamin D3 1,000–3,000 IU/day 维生素 D3 1,000–3,000 IU/天
Vitamin C 500–1,000mg twice a day 维生素 C 500–1,000mg 一天两次
Quercetin 250mg/day 槲皮素 250 mg/天
Zinc 30–40mg/day 锌 30–40 mg/天
Melatonin 6mg before bedtime (causes drowsiness)
睡前服用褪黑激素 6 mg（导致困倦）
..............................................................................................................
EARLY OUTPATIENT PROTOCOL3 早期门诊方案3
3 For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treatment Protocol for COVID-19 on www.flccc.net
3 对于晚期——住院患者——请参阅 www.flccc.net 上的 FLCCC 针对 COVID-19 的 MATH+ 医院治疗协议
lvermectin1
伊维菌素1
1 The safety of ivermectin in pregnancy has not been established. A discussion of benefits vs. risks with your provider is required prior to use, particularly in the 1st trimester.
1 伊维菌素在妊娠期的安全性尚未确定。 使用前需要与您的提供者讨论收益与风险的关系，尤其是在孕早期。
0.2–0.4 mg/kg per dose (take with or after meals) — one dose daily, take for 5 days or until recovered*
每剂 0.2–0.4 mg/kg（随餐或餐后服用）——每日一剂，服用 5 天或直至康复*
* The dosing may be updated as further scientific studies emerge.
随着进一步科学研究的出现，剂量可能会更新。
Use upper dose range if: ?1) in regions with more aggressive variants;2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors.
在以下情况下使用较高的剂量范围： 1) 在具有更侵袭性变异的区域；2) 在出现症状的第 5 天或之后或在肺部阶段开始治疗； 或 3) 多种合并症/风险因素。
Fluvoxamine 氟伏沙明
50mg twice daily for 10–14 days. 50mg，每天两次，持续 10-14 天。
Add to ivermectin if: 1) minimal response after 2 days of ivermectin;
2) in regions with more aggressive variants; 3) treatment started on or after day 5 of symptoms or in pulmonary phase; or 4) numerous comorbidities/risk factors. Avoid if patient is already on an SSRI.
在以下情况下添加到伊维菌素：1) 伊维菌素 2 天后反应最小；
2）在具有更激进变体的地区； 3) 在症状出现第 5 天或之后或在肺期开始治疗； 或 4) 多种合并症/风险因素。 如果患者已经在使用血清素再摄取抑制剂 (SSRI, 或简称为“血清素”，抗抑郁药) ，请避免使用。
PS. SSRI包括，Fluoxetine氟西汀 (Prozac百忧解)，Citalopram西?普兰 (Cipram舒忧膜衣锭)， Sertraline 舍曲林 (Zoloft乐复得膜衣锭)， Paroxetine帕罗西汀 (Seroxat克忧果膜衣锭)， Escitalopram离忧膜衣锭 (Lexapro立普能膜衣锭)
Nasopharyngeal Sanitation 鼻咽卫生
Steamed essential oil inhalation 3 times a day (i.e. vapo-rub) and/or chlorhexidine/benzydamine mouthwash gargles and Betadine nasal spray 2–3 times a day
每天 3 次蒸精油吸入（即 vapo-rub微克斯薄荷软膏）和/或
洗必泰漱口水(chlorhexidine氯己定)/得伏宁漱口水(benzydamine芐达明)漱口 和
和Betadine喷剂，每天 2-3 次
Vitamin D3 4,000 IU/day 维生素 D3 4,000 IU/天
Vitamin C 500–1,000mg twice a day 维生素 C 500–1,000 mg 一天两次
Quercetin 250mg twice a day 槲皮素 250 mg 一天两次
Zinc 100mg/day 锌 100 mg/天
Melatonin 10mg before bedtime (causes drowsiness)
睡前服用褪黑激素 10 mg（导致困倦）
Aspirin 325mg/day (unless contraindicated) 阿司匹林 325 mg/天（除非有禁忌）
Pulse Oximeter Monitoring of oxygen saturation is recommended
(for instructions please see page 2 of this file)
推荐使用脉搏血氧仪监测氧饱和度（有关说明，请参阅本文件的第 2 页）
For optional medicines and an overview of the developments in prevention and
treatment of COVID-19, please visit www.flccc.net/optional-medicines.
有关可选药物以及 COVID-19 预防和治疗进展的概述，请访问 www.flccc.net/optional-m
.....................................................................................
P.2
IVERMECTIN 伊维菌素
Summary of the Clinical Trials Evidence for Ivermectin in COVID-19
Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and antiinflammatory properties in laboratory studies. In the past 4 months, numerous, controlled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin.
COVID-19 中伊维菌素的临床试验证据总结
伊维菌素是一种抗寄生虫药物，其发现于 2015 年获得诺贝尔奖，已在实验室研究中证明其具有高效、抗病毒和抗炎特性。 在过去的 4 个月中，来自全球多个中心和国家的大量对照临床试验报告称，在接受伊维菌素治疗后，COVID-19 患者的预后得到了持续、大幅的改善。
Our comprehensive scientific review of these referenced trials on ivermectin can be found on
可在以下网址找到我们对这些伊维菌素参考试验的综合科学评论https://flccc.net/flccc-ivermectin-in-the-prophylaxis-and-treatment-of-covid-19/
For a quick overview, a One-page Summary of our review on ivermectin can be found on
如需快速概览，可在以下网址找到我们对伊维菌素评论的一页摘要
https://covid19criticalcare.com/one-page-summary-of-the-clinical-trials-evidence-for-ivermectin-in-covid-19/
...........................................................
Pulse Oximeter (usage instructions) 脉搏血氧仪（使用说明）
In symptomatic patients, monitoring with home pulse oximetry is recommended (due to asymptomatic hypoxia). The limitations of home pulse oximeters should be recognized, and validated devices are preferred. Multiple readings should be taken over the course of the day, and a downward trend should be regarded as ominous. Baseline or ambulatory desaturation < 94% should prompt hospital admission. The following guidance is suggested:
– Use the index or middle finger; avoid the toes or ear lobe
– Only accept values associated with a strong pulse signal
– Observe readings for 30–60 seconds to identify the most common value
– Remove nail polish from the finger on which measurements are made
– Warm cold extremities prior to measurement
对于有症状的患者，建议使用家庭脉搏血氧仪进行监测（由于无症状缺氧）。 应该认识到家用脉搏血氧仪的局限性，并首选经过验证的设备。 一天中应进行多次读数，应将下降趋势视为不祥之兆。 基线或动态去饱和度 < 94% 应立即入院。 建议采用以下指导：
– 使用食指或中指； 避开脚趾或耳垂
– 只接受与强脉冲信号相关的值
– 观察读数 30-60 秒以确定最常见的值
– 从进行测量的手指上去除指甲油
– 测量前先温暖寒冷的四肢
...........................................................................................
...........................................................................................
................................................................................................
晚期住院治疗方案: https://reurl.cc/1YmWOX
MATH+ HOSPITAL TREATMENT PROTOCOL FOR COVID-19
COVID-19 的 MATH+ 医院治疗方案
1. METHYLPREDNISOLONE 甲泼尼龙
INDICATION/INITIATION 指示/启动
A. Upon oxygen requirement or abnormal chest X-ray
A. 需氧或胸片异常
RECOMMENDED DOSING 推荐剂量
Preferred: 80mg IV bolus, then 40mg IV twice daily
Alternate: 80mg/240ml normal saline IV infusion at 10ml/hr
Follow COVID-19 Respiratory Failure protocol
(see flccc.net/respiratory-support-c19/)
首选：80 毫克静脉推注，然后每天两次 40 毫克静脉注射
替代：80 毫克/240 毫升生理盐水以 10 毫升/小时的速度静脉输注
遵循 COVID-19 呼吸衰竭协议
（见 flccc.net/respiratory-support-c19/）
TITRATION/DURATION 滴定/持续时间
A1. If no improvement in oxygenation in 2–4 days, double dose to 160?mg/daily.
A2. Upon need for FIO2 > 0.6 or ICU, escalate to “Pulse Dose” below (B)
A3. Once off IMV, NPPV, or High flow O2, decrease to 20?mg twice daily. Once off O2, then taper with 20?mg/day × 5 days then 10?mg/day × 5 days
A1. 如果在 2-4 天内氧合没有改善，则将剂量加倍至 160 mg/天。
A2。 当需要 FIO2 > 0.6 或 ICU 时，升级到下面的“脉冲剂量”（B）
A3. 停用 IMV、NPPV 或高流量 O2 后，每天两次减少至 20 mg。 一旦关闭 O2，然后逐渐减少 20 mg/天 × 5 天，然后 10 mg/天 × 5 天
INDICATION/INITIATION 指示/启动
B. Refractory Illness/Cytokine Storm
B. 难治性疾病/细胞因子风暴
RECOMMENDED DOSING 推荐剂量
“Pulse” dose with 125–250mg IV every 6 hours 每 6 小时静脉注射 125 –250 mg “脉冲”剂量
TITRATION/DURATION 滴定/持续时间
Continue × 3 days then decrease to 160?mg IV/ daily dose above, taper according to oxygen requirement (A). If no response or CRP/Ferritin high/rising, consider mega-dose IV ascorbic acid and/or “Therapeutic Plasma Exchange” below
继续 × 3 天，然后减少至 160 mg IV/上述每日剂量，根据需氧量逐渐减少 (A)。 如果没有反应或 CRP/铁蛋白高/升高，考虑大剂量静脉注射抗坏血酸和/或下面的“治疗性血浆置换”
...
2. ASCORBIC ACID 抗坏血酸 (维生素C)
INDICATION/INITIATION 指示/启动
O2 < 4L on hospital ward 医院病房的 O2 < 4 L
RECOMMENDED DOSING 推荐剂量
500–1000mg oral every 6 hours 每 6 小时口服 500-1000 毫克
TITRATION/DURATION 滴定/持续时间
Until discharge 直到出院
INDICATION/INITIATION 指示/启动
O2 > 4L or in ICU O2 > 4L 或在加护病房
RECOMMENDED DOSING 推荐剂量
50mg/kg IV every 6 hours 50 mg/kg 静脉注射 每 6 小时一次
TITRATION/DURATION 滴定/持续时间
Up to 7 days or until discharge from ICU, then switch to oral dose above
最多 7 天或直到从 ICU 出院，然后改用上述口服剂量
INDICATION/INITIATION 指示/启动
If in ICU and not improving 如果在加护病房并且没有改善
RECOMMENDED DOSING 推荐剂量
Consider mega-doses: 25 grams IV twice daily for 3 days
考虑大剂量：每天两次静脉注射 25 克，持续 3 天
TITRATION/DURATION 滴定/持续时间
Completion of 3 days of therapy 完成3天的治疗
...
3. THIAMINE 硫胺素
INDICATION/INITIATION 指示/启动
ICU patients 加护病房患者
RECOMMENDED DOSING 推荐剂量
200?mg IV twice daily 每天两次 200 mg 静脉注射
TITRATION/DURATION 滴定/持续时间
Up to 7 days or until discharge from ICU 最多 7 天或直到从 ICU 出院
…
4. HEPARIN (LMWH) 低分子量肝素
a.INDICATION/INITIATION 指示/启动
If initiated on a hospital ward
如果在医院病房开始
RECOMMENDED DOSING 推荐剂量
1?mg/kg twice daily —Monitor anti-Xa levels, target 0.6–1.1?IU/ml
每天两次 1 mg/kg — 监测抗 Xa 水平，目标为 0.6–1.1 IU/ml
TITRATION/DURATION 滴定/持续时间
Until discharge then start DOAC at half dose × 4 weeks
直到出院，然后开始直接口服抗凝血剂 DOAC 半剂量 × 4 周
b.INDICATION/INITIATION 指示/启动
If initiated in the ICU 如果在加护病房中启动
RECOMMENDED DOSING 推荐剂量
0.5?mg/kg twice daily —Monitor anti-Xa levels, target 0.2–0.5 IU/ml
每天两次 0.5 mg/kg — 监测抗 Xa 水平，目标为 0.2–0.5 IU/ml
TITRATION/DURATION 滴定/持续时间
Until discharge then start DOAC at half dose × 4 weeks
直到出院，然后开始直接口服抗凝血剂 DOAC 半剂量 × 4 周
…
5. IVERMECTIN?* (a core medication) 伊维菌素 *（一种核心药物）
* The safety of ivermectin in pregnancy has not been established thus treatment decisions require an assessment of the risks vs. benefits in a given clinical situation.
* 伊维菌素在怀孕期间的安全性尚未确定，因此治疗决策需要评估特定临床情况下的风险与收益。
INDICATION/INITIATION 指示/启动
Upon admission to hospital and/or ICU 入院和/或 加护病房时
RECOMMENDED DOSING 推荐剂量
0.4–0.6 mg/kg per dose — daily (Take with or after meals)
每剂 0.4–0.6 mg/kg — 每天（随餐服用或餐后服用）
TITRATION/DURATION 滴定/持续时间
For 5 days or until recovered 5 天或直至康复
…
6. Fluvoxamine 氟伏沙明
INDICATION/INITIATION 指示/启动
Hospitalized patients 住院病人
RECOMMENDED DOSING 推荐剂量
50?mg PO twice daily 每天两次 口服50 mg
TITRATION/DURATION 滴定/持续时间
10–14 days 10–14 天
…
7. Cyproheptadine 佩你安锭
INDICATION/INITIATION 指示/启动
If any of:
1) on fluvoxamine,
2) hypoxemic,
3) tachypneic/respiratory distress,
4) oliguric/kidney injury
如果有：
1) 氟伏沙明，
2) 缺氧，
3) 呼吸急促/呼吸窘迫，
4) 少尿/肾损伤
RECOMMENDED DOSING 推荐剂量
8?mg — 3 x daily 8 mg — 每天 3 次
TITRATION/DURATION 滴定/持续时间
until discharge, slow taper once sustained improvements noted
直到出院，一旦注意到持续改善，逐渐减少
…
8.Anti-Androgen Therapy 抗雄激素治疗
INDICATION/INITIATION 指示/启动
Hospitalized patients (Men only) 住院患者（仅限男性）
RECOMMENDED DOSING 推荐剂量
Dutasteride 0.5?mg daily or Finasteride 5?mg daily
度他雄胺每天 0.5 mg 或非那雄胺 5 mg 每天
TITRATION/DURATION 滴定/持续时间
until fully recovered 直到完全康复
…
9. Vitamin D 维生素D
INDICATION/INITIATION 指示/启动
Hospitalized patients 住院病人
RECOMMENDED DOSING 推荐剂量
Calcifediol preferred: 0.5?mg PO day 1, then 0.2?mg PO day 2 and weekly thereafter Cholecalciferol: 20,000–60,000 IU single dose PO then 20,000 IU weekly
首选骨化二醇：第 1 天口服0.5 mg ，第 2 天然后口服0.2 mg ，之后每周 胆钙化醇：口服20,000–60,000 IU 单剂量 ，然后每周 20,000 IU
TITRATION/DURATION 滴定/持续时间
Until discharge 直到出院
…
10. Atorvastatin 阿托伐他汀
INDICATION/INITIATION 指示/启动
ICU Patients 加护病房患者
RECOMMENDED DOSING 推荐剂量
80?mg PO daily 每天 口服80 mg
TITRATION/DURATION 滴定/持续时间
Until discharge 直到出院
…
11.Melatonin 褪黑激素
INDICATION/INITIATION 指示/启动
Hospitalized patients 住院病人
RECOMMENDED DOSING 推荐剂量
6–12?mg PO at night 晚上口服6–12 mg
TITRATION/DURATION 滴定/持续时间
Until discharge 直到出院
…
12.Zinc 锌
INDICATION/INITIATION 指示/启动
Hospitalized patients 住院病人
RECOMMENDED DOSING 推荐剂量
75–100?mg PO daily 每天口服75–100 mg
TITRATION/DURATION 滴定/持续时间
Until discharge 直到出院
…
13.Famotidine 法莫替丁
INDICATION/INITIATION 指示/启动
Hospitalized patients 住院病人
RECOMMENDED DOSING 推荐剂量
40–80?mg PO twice daily 每天两次 口服40–80 mg
TITRATION/DURATION 滴定/持续时间
Until discharge 直到出院
…
14.Therapeutic Plasma Exchange 治疗性血浆交换
INDICATION/INITIATION 指示/启动
Patients refractory to pulse dose steroids 脉冲剂量类固醇难治的患者
RECOMMENDED DOSING 推荐剂量
5 sessions, every other day 5 节，每隔一天
TITRATION/DURATION 滴定/持续时间
Completion of 5 exchanges 完成5次交换
......................................................................
Legend: CRP = C-Reactive Protein, DOAC = direct oral anti-coagulant, FiO2 = Fraction of inspired oxygen, ICU = Intensive Care Unit, IMV = Invasive Mechanical Ventilation, IU = International units, IV =intravenous, NIPPV = Non-Invasive Positive Pressure Ventilation, O2 = oxygen, PO (per os) = oral administration
图例：CRP = C-反应蛋白，DOAC = 直接口服抗凝剂，FiO2 = 吸入氧分数，ICU = 加护病房，IMV = 有创机械通气，IU = 国际单位，IV = 静脉，NIPPV = 非侵入性 正压通气，O2 = 氧气，PO (per os) = 口服
For updates, references and more information on MATH+ (Hospital Treatment Protocol for COVID-19) and on our I-MASK+ (Prevention & Early Outpatient Treatment Protocol for COVID-19) please see flccc.net
有关 MATH+（COVID-19 的医院治疗协议）的更新、参考和更多信息
以及关于我们的 I-MASK+（COVID-19 的预防和早期门诊治疗协议），请参阅 flccc.net
...............................
控制炎症和过度凝血
In all COVID-19 hospitalized patients, the therapeutic focus must be placed on early intervention utilizing powerful, evidence based therapies to counteract:
— The overwhelming and damaging inflammatory response
— The systemic and severe hyper-coagulable state causing organ damage
By initiating the protocol soon after a patient meets criteria for oxygen supplementation, the need for mechanical ventilators and ICU beds will decrease dramatically.
在所有 COVID-19 住院患者中，治疗重点必须放在早期干预上，利用强大的循证疗法来抵消：
— 压倒性和破坏性的炎症反应
— 导致器官损伤的全身性和严重的高凝状态
通过在患者达到供氧标准后立即启动方案，对机械呼吸机和 加护病房 床位的需求将显著减少。
...........................
TREATMENT OF LOW OXYGEN 低氧处理
— If patient has low oxygen saturation on nasal cannula, initiate heated high flow nasal cannula.
— Do not hesitate to increase flow limits as needed.
— Avoid early intubation that is based solely on oxygen requirements. Allow “permissive hypoxemia” as tolerated.
— Intubate only if patient demonstrates excessive work of breathing.
— Utilize “prone positioning” to help improve oxygen saturation.
— 如果患者的鼻插管氧饱和度低，则开始使用加热的高流量鼻插管。
— 毫不犹豫地根据需要增加流量限制。
— 避免仅基于氧气需求的早期插管。 允许“允许性低氧血症”。
— 仅当患者表现出过度呼吸做功时才插管。
— 利用“俯卧位”来帮助提高氧饱和度。
..................................
ABOUT THE MATH+ HOSPITAL TREATMENT PROTOCOL FOR COVID-19
关于 COVID-19 的 MATH+ 医院治疗方案
Our MATH+ protocol is designed for hospitalized patients, to counter the body’s overwhelming inflammatory response to the SARS-CoV-2 virus. The protocol is based on numerous medical journal publications over decades. It is the hyper-inflammation, not the virus itself, that damages the lungs and other organs and ultimately causes death in COVID-19. We have found the MATH+ protocol to be a highly effective combination therapy in controlling this extreme inflammatory response and we have now added
ivermectin as a core component given the profound emerging efficacy data in hospitalized patients reviewed here (www.flccc.net/flccc-ivermectin-review-covid-19).
The steroid Methylprednisolone is a key component, increasing numbers of studies (see https://flccc.net/medical-evidence) show its profound effectiveness in COVID-19, which is made more potent when administered intravenously with high doses of the antioxidant Ascorbic acid given that the two medicines have multiple synergistic physiologic effects. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. Theanticoagulant Heparin is
important for preventing and dissolving blood clots that appear with a very high frequency in patients not given blood thinners. The + sign indicates several important co-interventions that have strong physiologic rationale and an excellent safety profile. It also indicates that we plan to adapt the protocol as our insights and the published medical evidence evolve.
Timing is a critical factor in the successful treatment of COVID-19. Patients must go to the hospital as soon as they experience difficulty breathing or have a low oxygen level. The MATH+ protocol then should be administered soon after a patient meets criteria for oxygen supplementation (within the first hours after arrival in the hospital), in order to achieve maximal efficacy as delayed therapy has led to complications such as the need for mechanical ventilation.
If administered early, this formula of FDA-approved, safe, inexpensive, and readily available drugs can eliminate the need for ICU beds and mechanical ventilators and return patients to health.
我们的 MATH+ 方案专为住院患者设计，以对抗身体对 SARS-CoV-2 病毒的强烈炎症反应。该案基于数十年来的众多医学期刊出版物。损害肺部和其他器官并最终导致 COVID-19 死亡的是过度炎症，而不是病毒本身。我们发现 MATH+ 方案是控制这种极端炎症反应的高效联合疗法，鉴于此处审查的住院患者的深刻新兴疗效数据，我们现在添加了伊维菌素作为核心成分（www.flccc.net/flccc-ivermectin -review-covid-19）。
类固醇甲基强的松龙是一个关键成分，越来越多的研究（见 https://flccc.net/medical-evidence）表明其对 COVID-19 的疗效显著，当静脉注射高剂量抗坏血酸抗坏血酸时，效果更佳考虑到这两种药物具有多种协同生理作用。硫胺素用于优化细胞氧利用和能量消耗，保护心脏、大脑和免疫系统。抗凝剂肝素对于预防和溶解在未服用血液稀释剂的患者中出现频率非常高的血凝块很重要。 + 号表示几种重要的联合干预措施，它们具有很强的生理学原理和出色的安全性。它还表明我们计划随着我们的见解和已发表的医学证据的发展而调整案。
时间是成功治疗 COVID-19 的关键因素。患者一旦呼吸困难或氧气含量低，必须立即去医院。在患者符合氧气补充标准后（在抵达医院后的最初几个小时内）应立即实施 MATH+ 方案，以实现最大疗效，因为延迟治疗会导致并发症，例如需要机械通气。
如果及早给药，这种经 FDA 批准、安全、廉价且易于获得的药物配方可以消除对 ICU 病床和机械呼吸机的需求，并使患者恢复健康。
DISCLAIMER
This protocol is solely for educational purposes regarding potentially beneficial therapies for COVID-19. Never disregard professional medical advice because of something you have read on our website and releases. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment in regards to any patient. Treatment for an individual patient should rely on the judgement of your physician or other qualified health provider. Always seek their advice with any questions you may
have regarding your health or medical condition.
免责声明
该协议仅用于有关 COVID-19 潜在有益疗法的教育目的。 永远不要因为您在我们的网站上阅读过的内容和发布的内容而忽视专业的医疗建议。 它不能替代对任何患者的专业医疗建议、诊断或治疗。 对个别患者的治疗应取决于您的医生或其他合格医疗保健提供者的判断。 如果您对自己的健康或医疗状况有任何疑问，请始终寻求他们的建议。
...................................
The FLCCC Alliance – On a Mission to Save Thousands & Slow the Pandemic (A brief self-introduction; Jan 19, 2021)
The FLCCC Alliance was organized in March, 2020 by a group of highly published, world renowned Critical Care physician/scholars – with the academic support of allied physicians from around the world – to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. Their MATH+ Hospital Treatment Protocol – introduced in March, 2020, has saved tens of thousands of patients who were critically ill with COVID-19. Now, the FLCCC’s new I-Mask+
Prophylaxis and Early At-Home Outpatient Treatment Protocol with ivermectin has been released – and is a potential solution to the global pandemic.
FLCCC 联盟——拯救数千人和减缓大流行的使命（简短的自我介绍；2021 年 1 月 19 日）
FLCCC 联盟于 2020 年 3 月由一群高度发表的、世界知名的重症监护医师/学者在来自世界各地的专职医师的学术支持下组织，旨在研究和制定预防和治疗 COVID- 19 在疾病的所有阶段。 他们于 2020 年 3 月推出的 MATH+ 医院治疗协议已挽救了数万名 COVID-19 危重患者。 现在，FLCCC 新的 I-Mask+ 预防和伊维菌素早期在家门诊治疗方案已经发布——这是全球大流行的潜在解决方案。